找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Management of Pancreatic Cancer and Cholangiocarcinoma; Hiroyuki Isayama,Yousuke Nakai,Takashi Sasaki Book 2021 The Editor(s) (if applicab

[復(fù)制鏈接]
查看: 19714|回復(fù): 53
樓主
發(fā)表于 2025-3-21 19:42:08 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma
編輯Hiroyuki Isayama,Yousuke Nakai,Takashi Sasaki
視頻videohttp://file.papertrans.cn/623/622569/622569.mp4
概述Covers recent topics in epidemiology, examination, treatment and endoscopic management of pancreatobiliary malignancies.Will appeal to surgeons, endoscopists and oncologists.Explores risk factors and
圖書封面Titlebook: Management of Pancreatic Cancer and Cholangiocarcinoma;  Hiroyuki Isayama,Yousuke Nakai,Takashi Sasaki Book 2021 The Editor(s) (if applicab
描述.This comprehensive book presents the latest evidence-based data on pancreatobiliary malignancies, including the epidemiology, examination, treatment and endoscopic management. It explores a range of topics, such as risk factors, detection strategies, and novel treatment approaches like precision medicine and immunotherapy..Although there have been rapid improvements in the management of these diseases, the survival period has not yet reached a satisfactory level. This book will help those doctors needing to share the latest information with the patients and their families. It provides a wealth of practical information to help surgeons, endoscopists and oncologists as well as physicians, basic researchers and professionals at medical device and pharmaceutical companies broaden their understanding of the current treatment and management strategies for pancreatobiliary malignancies..
出版日期Book 2021
關(guān)鍵詞Pancreas Cancer; Bile Duct Cancer; Cholangiocarcinoma; Surgery; Endoscopic Treatment; Interventional EUS;
版次1
doihttps://doi.org/10.1007/978-981-16-2870-2
isbn_softcover978-981-16-2872-6
isbn_ebook978-981-16-2870-2
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapor
The information of publication is updating

書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma影響因子(影響力)




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma影響因子(影響力)學科排名




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma網(wǎng)絡(luò)公開度




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma網(wǎng)絡(luò)公開度學科排名




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma被引頻次




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma被引頻次學科排名




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma年度引用




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma年度引用學科排名




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma讀者反饋




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma讀者反饋學科排名




單選投票, 共有 1 人參與投票
 

1票 100.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 22:45:44 | 只看該作者
Book 2021and endoscopic management. It explores a range of topics, such as risk factors, detection strategies, and novel treatment approaches like precision medicine and immunotherapy..Although there have been rapid improvements in the management of these diseases, the survival period has not yet reached a s
板凳
發(fā)表于 2025-3-22 03:44:42 | 只看該作者
地板
發(fā)表于 2025-3-22 05:53:47 | 只看該作者
5#
發(fā)表于 2025-3-22 10:40:35 | 只看該作者
6#
發(fā)表于 2025-3-22 13:08:02 | 只看該作者
7#
發(fā)表于 2025-3-22 18:51:00 | 只看該作者
8#
發(fā)表于 2025-3-22 22:11:03 | 只看該作者
Radiotherapy for Pancreatic Cancern. The life-prolonging effect of radiotherapy has not yet been clearly demonstrated, but it has been shown to lead to improved local control. In this chapter, we will introduce radiotherapy for pancreatic cancer, focusing on the heavy-ion radiotherapy that we are performing.
9#
發(fā)表于 2025-3-23 05:19:42 | 只看該作者
Conversion Surgery in Pancreatic Cancerthere are no robust data which indicate the clear benefit of CS and no consensus of the indication and optimal timing of CS for initially unresectable pancreatic cancer. Several prospective clinical trials are ongoing to clarify the benefit of CS for UR-PDAC.
10#
發(fā)表于 2025-3-23 09:11:43 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-11-1 21:18
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
普兰店市| 永登县| 普兰县| 萨嘎县| 伊川县| 南京市| 灵宝市| 宁乡县| 呼图壁县| 平阳县| 阿拉善右旗| 虞城县| 达州市| 垣曲县| 黄大仙区| 新乡县| 搜索| 广东省| 江门市| 巴林右旗| 法库县| 新晃| 清流县| 宁南县| 新闻| 丹阳市| 隆安县| 琼结县| 辛集市| 西乌| 南平市| 司法| 准格尔旗| 顺平县| 梅河口市| 涟源市| 夏津县| 新昌县| 烟台市| 台前县| 临猗县|